US pharmaceutical firm developing mRNA vaccines, including flu vaccine approved by FDA and melanoma vaccine in trials with Merck.
Verbatim sentences from the source article.
Citizen Digital
Merck, Moderna claim 'promising' skin cancer vaccine results in key trial By AFP August 19, 2026 05:41 (EAT) Add as a Preferred Source on Google Follow us Follow on Whatsapp Follow on Google Follow on Twitter Audio By Vocalize US pharmaceutical firms Merck and Moderna announced W …
Merck, Moderna claim 'promising' skin cancer vaccine results in key trialThe Standard
Audio By VocalizeVaccine manufacturer Moderna said Wednesday the US Food and Drug Administration (FDA) had approved its new influenza vaccine, nearly six months after the regulator briefly rejected an application for review. …
US regulators approve Moderna flu vaccineCitizen Digital
… On Tuesday, Canada gave the go-ahead to US pharmaceutical giant Moderna to begin clinical trials of a vaccine against the Bundibugyo strain of Ebola. …
WHO chief in DR Congo for talks on Ebola reponseThe Standard
… On Tuesday, Canada gave the go-ahead to US pharmaceutical giant Moderna to begin clinical trials of a vaccine against the Bundibugyo strain of Ebola.The vaccine, said by the WHO as "the most promising" -- the rVSV Bundibugyo -- will also be developed by Singapore-based Hilleman L …
WHO chief in DR Congo for talks on Ebola reponseCitizen Digital
… The two front-running candidate vaccines are one using the ChAdOx1 platform, being developed by the University of Oxford and the Serum Institute of India, and another being worked on by US pharma firm Moderna using mRNA technology. …
WHO pleads for more support to tackle Ebola outbreakCapital News
… Leading candidates include vaccine programs developed by the University of Oxford in partnership with the Serum Institute of India, as well as mRNA-based vaccines from Moderna. …
US Sends Experimental Ebola Drug to Support Clinical Trials in DR CongoCitizen Digital
… The first to reach testing is likely one developed by Oxford and the Serum Institute of India, alongside another from U.S. vaccine maker Moderna based on mRNA technology. …
US provides Ebola treatment for outbreak in Congo, bringing trials closerCitizen Digital
… The first to reach testing is likely one developed by Oxford and the Serum Institute of India, alongside another from U.S. vaccine maker Moderna based on mRNA technology. …
US provides Ebola treatment for outbreak in Congo, bringing trials closerThe Standard
… US pharma firm Moderna is working on its own Bundibugyo vaccine that uses the mRNA technology it pioneered against Covid.The Oxford and Moderna vaccines could be ready to start phase 1 trials in humans in two to three months, the Coalition for Epidemic Preparedness Innovations (C …
The vaccines and treatments being developed for Ebola outbreakCitizen Digital
… CEPI also said it had committed $50 million to a vaccine candidate being developed by US pharma giant Moderna which uses the mRNA technology pioneered in its Covid vaccine. …
'We need to act now': Race to develop Ebola vaccine heats upUS pharmaceutical firms Merck and Moderna announced encouraging results from a trial of their experimental vaccine against melanoma, called intismeran autogene, which showed "statistically significant and clinically meaningful improvements" for skin cancer patients when used with Merck's Keytruda treatment.
17 hours ago · Citizen Digital →
US pharmaceutical firms Merck and Moderna announced encouraging results from a trial of their experimental vaccine against melanoma, called intismeran autogene, which showed "statistically significant and clinically meaningful improvements" for skin cancer patients when used with Merck's Keytruda treatment.
17 hours ago · Citizen Digital →
Moderna announced the US Food and Drug Administration approved its mFLUVISA flu vaccine for adults age 50 and older, with the company expecting availability for the 2026-2027 respiratory virus season. The FDA had initially rejected the application in February before reversing its decision a week later.
6 August 2026 · The Standard →
The World Health Organization's Director-General arrived in the Democratic Republic of Congo for talks with President Felix Tshisekedi as the country's 17th Ebola outbreak spreads at an "exceptional" pace. The outbreak, declared on May 15, has recorded 3,874 confirmed cases and 1,751 deaths.
6 August 2026 · Citizen Digital →
The WHO director general has arrived in the Democratic Republic of Congo for meetings with President Felix Tshisekedi as the Ebola epidemic spreads at an "exceptional" pace. The country's 17th Ebola outbreak, declared in May, has recorded 3,874 confirmed cases and 1,751 deaths, with the Bundibugyo virus variant currently lacking a vaccine or treatment.
5 August 2026 · The Standard →
The World Health Organization called for more financial and other resources to combat the Ebola outbreak in the Democratic Republic of Congo, which it described as the biggest ever to have hit the DRC and is still expanding beyond the capacity of response efforts. There have been 3,802 confirmed cases with 1,707 deaths, according to WHO figures.
5 August 2026 · Citizen Digital →
The United States has provided doses of an experimental antibody drug developed by Mapp Biopharmaceutical to support clinical trials in the Democratic Republic of Congo's Ebola outbreak, marking a shift from prior US-only availability. The move comes as health authorities work to contain a rapidly spreading Bundibugyo strain outbreak that has recorded more than 1,000 cases and over 250 deaths.
24 June 2026 · Capital News →
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for clinical trials in the Democratic Republic of Congo's Bundibugyo Ebola outbreak, which has caused over 1,000 cases and more than 250 deaths. The trial data could inform future U.S. regulatory review and potential approval.
24 June 2026 · Citizen Digital →
The U.S. has provided doses of an experimental antibody drug from Mapp Biopharmaceutical for use in clinical trials and compassionate use to fight an Ebola outbreak in Democratic Republic of Congo. The Bundibugyo strain has caused more than 1,000 cases in Congo and more than 250 deaths, with a handful of cases also reported in Uganda.
24 June 2026 · Citizen Digital →
More than 875 cases of the Bundibugyo Ebola strain have been confirmed, including 202 deaths, in a little over a month across DR Congo and Uganda, with no currently available vaccines or treatments for this strain. Scientists and pharmaceutical companies are racing to develop new vaccines and treatments, with the WHO calling an rVSV-based vaccine candidate "most promising" and estimating it will take seven to nine months before human testing can begin.
18 June 2026 · The Standard →
Non-profit organisations announced Monday they are ramping up efforts to develop a vaccine for the Bundibugyo strain of Ebola, which has caused an outbreak in the Democratic Republic of Congo and Uganda with nearly 250 suspected deaths and more than 1,100 infections. The strain, for which there are no approved vaccines or treatments, has prompted a race to rapidly develop, manufacture and test a vaccine in clinical trials in the affected region.
1 June 2026 · Citizen Digital →